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Abstract
Autism is a neurodevelopmental disorder characterized by social, communication, and
behavioral symptoms. Recent research has attempted to identify the potential mecha‐
nisms that may contribute to the pathogenesis of autism. Biomarkers as noninvasive
quantitative biological measures with accurate indication of a specific mechanism can
lead to a better understanding of the pathogenesis required to design the most effective
treatments of autism. There is also great hope that the discovery of valid and predictive
biomarkers for this disorder will help earlier and more targeted methods for diagnosis
and intervention. In this chapter, we discuss some of the current theorized mechanisms
contributing to autism, including inflammation, oxidative stress, impaired detoxifica‐
tion, glutamate excitotoxicity, gut-microbiota-brain axis, impaired fatty acid profiling,
and serotonin (5-HT)/oxytocin (OT) abnormalities as target to treat autism. Moreover,
based on our understanding of the role of these mechanisms, selected treatment strategies
are suggested. These strategies include nutraceuticals, probiotics/prebiotics and ω-3
supplementation, targeting glutamate transporters or selective 5-HT reuptake inhibi‐
tors, and intranasal OT treatment. Of course, the joint efforts of scientists, caregivers, and
other stakeholders must combine to identify valid, clinically useful autism biomarkers
that may lead to efficient treatment strategy and/or combined strategies.
Keywords: autism, biomarkers, excitotoxicity, neuroinflammation, nutraceuticals,
ω-3, oxidative stress, probiotic
1. Introduction
Autism is a neurodevelopmental disorder characterized by deficits in cognition and learning,
behavior,  social  interaction,  and  communication.  Among the  challenging  behaviors  that
negatively affect the child with autism is the social interaction impairment. Social interaction is
defined as how an individual uses verbal and nonverbal communication during interperso‐
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nal exchanges. Children with autism usually present difficulty in recognizing the thoughts and
feelings of others, and this is described as “mind blindness,” which can lead to ineffective
communication [1]. Cognitive differences are also prevalent in children with autism. As a result,
academic differences often exist due in part to weaknesses with executive functioning. The
current management strategies, practice, and methods are put into place by professionals,
researchers, and parents to compensate for the deficits in these areas. They are designed and
selected in hopes of producing the maximum improvement in autistic behavior.  Genetic
heterogeneity was recorded earlier in twin, family, and linkage studies. The autism-related
genes seem to be contributed on few etiological pathways related to detoxification, synaptic
function, and neurogenesis [2–5]. As genes and environment rarely act independently to induce
autism, the interaction between both at various developmental times usually plays an impor‐
tant role in the pathology of this disorder. Because development is a dynamic process, a constant
interplay between genes and environment usually occurs [6]. Although the progressive increase
in the prevalence of autism can be attributed to the increase in public awareness and the
broadening of diagnostic construct, of course, it can be also related to the incidence of environ‐
mental factors [7, 8] and their interactions with yet unknown genetic vulnerability. Nutrients,
heavy metal pollution, medications, and pesticides as the most commonly examined expo‐
sures during pregnancy are among the environmental neurotoxic insult on developing brains.
Understanding  how low-level  chemical  exposures  influence  the  molecular,  cellular,  and
behavioral outcomes relevant to autism will provide insight regarding gene-environment
interactions and possibly yield novel intervention strategies. There is no metabolic biomarker
or panel of markers that can precisely define autism, but examining different signaling pathways
to identify any abnormalities in autistic patients compared to their normal peers can be enhanced
to treat autism through the amelioration of these defected pathways.
Figure 1. Role of genetic, environmental, and biological mechanisms in the etiology of autism.
Role of Biomarkers in Medicine206
Many studies related to the screening of biomarkers of autism were successful enough and
reproducible to ascertain the role of oxidative stress, environmental toxicants, mitochondrial
dysfunction, and immunology/inflammation as four main etiopathological mechanisms of
autism. In addition, there is accumulating evidence pointing to the contribution of lipid
abnormalities, gut microbiota, and glutamate excitotoxicity in generating biomarkers related
to autism. Figure 1 demonstrates the relationship between genetic, environmental, and
biological mechanisms in the etiology of autism.
2. Biomarkers related to autism
Screening for antioxidants includes the measurement of glutathione (GSH) as the primary
antioxidant entrusted with the protection against oxidative stress, neuroinflammation, and
mitochondrial damage. GSH is critically important in regulating the detoxification mechanism
and modulating the production of oxidative stress-related parameters. Measuring reduced
GSH, oxidized GSH (GSSG), or GSH status (GSH/GSSG) proves to be of great use in the
determination of the patient’s oxidation status. In a trial that evaluated the detoxification
mechanism in autism, a systematic review of 39 studies was conducted. It proved that many
patients with autism have lower GSH/GSSG, indicating poor antioxidant and detoxification
mechanisms [9]. Among the recorded detoxification markers that are studied in autism are p-
hydroxyphenyllactate, pyroglutamate, benzoate, and hippurate. Elevated levels of hippurate
and benzoate are related to impaired phase II detoxification via glycine conjugation [10].
Abnormal levels of pyroglutamate can indicate an impairment of GSH metabolism and a
depleted GSH status.
In more recent studies, serum thioredoxin levels and F2-isoprostane are related to cognitive
and social impairment severity in autistic patients [measured by Childhood Autism Rating
Scales (CARS) or Social Responsiveness Scale (SRS), respectively] [11–13]. A negative correla‐
tion between GSH peroxidase and CARS has also been reported [11]. Many studies prove that
oxidative stress can easily be related to chronic inflammation, glutamate excitotoxicity, and
increased mitochondrial dysfunction as etiological mechanisms in autism [14]. Additionally,
the observed cellular damage in these patients may range from structural damage and mitotic
arrest to apoptosis and cell necrosis depending on the severity of oxidative stress.
Figure 2 demonstrates the suggested relationship between these etiological mechanisms and
apoptosis of neurons that might lead to abnormal brain maturation that presents as autistic
features and behavioral deficits. Glutamate excitotoxicity, oxidative stress, and neuroinflam‐
mation are signaling pathways that might cause an increase and/or decrease of proapoptotic
and antiapoptotic proteins, respectively. Under the effect of genetic change or the environment
(e.g., heavy metal toxicity and altered gut microbiota), the activation of pathological apoptosis
(elevation of caspases) impairs normal brain maturation and induces autistic phenotype.
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Figure 2. Suggested relationship between oxidative stress, glutamate excitotoxicity, neuroinflammation, and pathologi‐
cal apoptosis leading to autistic phenotype.
The realization that the microbiota-gut-brain axis plays a critical role in the etiology of autism
has recently emerged. The regulation of this axis is essential for maintaining homeostasis,
including that of the central nervous system (CNS). Nowadays, understanding microbiota-
brain interactions has become exciting area of research, which may contribute new insights
into individual variations in cognition, social interaction, mood, and sleep disorders as
characteristic features of patients with autism [15, 16]. The ability of gut microbiota to com‐
municate with the brain and in turn induce behavioral changes is emerging as an interesting
concept in autism. The brain-gut axis is a bidirectional communication system composed of
neural pathways, such as the enteric nervous system (ENS), vagus, sympathetic, and spinal
nerves, as well as humoral pathways, which include cytokines, hormones, and neuropeptides
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as signaling molecules [16]. Brain excitotoxicity, oxidative stress, and neuroinflammation can
directly or indirectly affect the composition of the gut microbiota. On the contrary, microbial
overgrowth and their metabolites can modulate the brain normal function. Figure 3 demon‐
strates the suggested bidirectional interaction between the gut-microbiota and the brain as an
etiological mechanism in autism.
Figure 3. Gut-brain axis: pathways of communication between brain and gut microbiota.
This fact was confirmed by a study that has suggested a significant risk of autism in children
born to mothers with severe infections during pregnancy [17]. Additionally, offspring of
pregnant female monkeys exposed to antibodies produced postinfection usually develop
pathologies of the CNS and exhibited behavioral changes similar to those seen in autistic
children [18]. Autoantibodies triggered by systemic inflammation are generated during
pregnancy and are now accepted to play a role in abnormal neurological and impaired blood-
brain barrier (BBB) development in the fetus with a concomitant increased risk of autism [19].
The molecular trigger for autoantibody generation is poorly understood, but there is a
possibility that autoantibodies against receptors for key microbiota metabolites, such as
serotonin (5-HT), γ-aminobutyric acid (GABA), glutamate, tryptophan, and short-chain fatty
acids (SCFA), may be directed by the immune system under conditions of aberrant metabolite
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accumulation in the blood as well as inappropriate immune system in early life or mimicry by
gut bacteria [20].
These early observations provide a potential explanation for the gastrointestinal problems
suffered by patients with autism. In support of this line of thinking, children with autism are
shown to have increased permeability of the gastrointestinal tract, called “leaky gut,” causing
microbial products to escape into the bloodstream and possibly reach the brain [21]. These
products alter the immune system, resulting in a progression of the disease [22]. Differences
in the gut microbiota between maternal infection activated (MIA) offspring and controls are
observed due primarily to changes in the diversity of Clostridia and Bacteroidia [23]. The
intestines of some autistic patients with intestinal abnormalities are known to bear Sutterella
and Clostridium bolteae [24], organisms lacking in control populations with similar gastroin‐
testinal problems, together with lower Bifidobacterium and Lactobacillus species. Table 1
demonstrates altered gut microbiota in individuals with autism in relation to social impair‐
ment.
Autism
Significantly ↑ in Clostridium histolyticum [24]
Significantly ↑ in Bacteroidetes [25]
Significantly ↓ in species of Bifidobacterium and ↑ in Lactobacillus [26]
Significantly ↓ in species of Bifidobacterium spp. [27]
Significantly ↓ in Bacteroidetes, ↑ in Firmicutes: Bacteroidetes, ↑ in Betaproteobacteria [28]
Significant ↑ in Sutterella spp. [29]
Significant ↑ in Clostridium [30]
↑ in Clostridium, Bacteroidetes, Prophyromonas, Prevotella, Pseudomonas, Aeromonas, and Enterobacteriaceae; ↓ in
Enterococcus, Lactobacillus, Streptococcus, and Staphylococcus [31]
Table 1. Association between gut microbiota altered composition and social impairment as core symptom in autistic
patients.
The metabolomic studies of urine from patients with autism have identified molecules
associated with the microbiome, such as dimethylamine, hippuric acid, and phenylacetylglut‐
amine [24, 32]. Decreased plasma levels of p-hydroxyphenyllactate, the metabolite of Bifido‐
bacterium and Lactobacillus, which is known to serve as an antioxidant both in the circulation
and tissues, were also detected in urine of patients with autism [33].
SCFA, such as acetate, propionate, and butyrate, are neuroactive microbial metabolites that
can cross the BBB and induce remarkable changes in brain function during development and
thus lead to behavior abnormalities [34–36]. Increased levels of total as well as individual SCFA
levels have been associated with autism [37]. Propionate has also been shown to induce
behavioral changes similar to autism when infused interventricularly to the brain [35]. It was
also reported that increased butyrate levels in valproic acid (VPA) in utero-exposed male
offspring could contribute to deficits in social behavior. Both butyrate and VPA neurotoxicity
are associated with the impairment of fatty acids transport by the carnithine pathway. This
Role of Biomarkers in Medicine210
can easily be related to mitochondrial dysfunction as an etiological mechanism in autism [34].
Both acids can also relate to intestinal inflammatory phenotype common in autistic patients
through their inhibitory effects on histone deacetylase in the gut of exposed animals [38].
Modulating intestinal mucus composition through MUC-2 gene expression can affect epithe‐
lial protection, gut morphology, and gut microbiota composition [39]. Moreover, if blood
butyrate levels are increased, it can affect various neuronal cells directly and thereby affect the
maturation of oligodendrocytes and hippocampal neuronal cells in the brain during postnatal
development and induce autistic features in treated animals [40, 41].
In the case of neurodevelopmental disorders, such as autism, the neuroimmune system could
affect not only function but also brain development [42]. The inflammatory response elicited
during pregnancy in the mother can induce inflammation in the fetus through the placenta [43].
Clinical and postmortem studies have shown that neuroinflammatory processes induced
during the prenatal period usually remain altered throughout autism pathology. Abnormal
inflammatory response to infection of different blood cell populations has been described in
autistic children, and such patients usually suffer from chronic gastrointestinal disturbances
[24, 37, 44]. It is well known that their mononuclear cells and lymphoblasts produce excessive
proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and
IL-1β, both basally [45] and after being stimulated with lipopolysaccharides (LPS) [46],
Figure 4. Early inflammation as an etiological mechanism in autism.
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compared to healthy controls. Astrogliosis and microglial activation, together with the
overexpression of cytokines in different regions of the autistic brain, show that autistic patients
demonstrate an altered neuroinflammatory response throughout their lives; they also show
increased astrocyte and microglia inflammatory response in the cortex and the cerebellum [47,
48]. Moreover, increased expression of interferon-γ (IFN-γ), monocyte chemoattractant
protein-1 (MCP-1), transforming growth factor-β1 (TGF-β1), IL-8, IL-6, and TNF-α and other
genes associated with the immune response have been reported in those brain regions and in
the cerebrospinal fluid [48–50] (Figure 4).
In a 2D gel-based proteomic analysis of urine, a total of 250 protein spots were detected in
autistic samples compared to 195 in normal control subjects. Whereas 10 proteins were
overexpressed, others were found to be underexpressed. Out of the significantly different urine
analysis, three overexpressed peptides were identified as kininogen-1 (KNG-1)-50, IgG1 heavy
chain variable region, and mannan-binding lectin serine protease-2 isoform-2 precursor-45.
The abnormal formation of KNG-1 as an important regulator of urokinase plasminogen
activator receptor is involved in cell migration and proliferation [51]. The increase of urinary
KNG-1 levels in all the tested autistic children highlights the possibility of using this protein
as a diagnostic marker.
Significant changes in the levels of aspartate, citrate, creatinine, hydroxyphenyllactate,
indoleacetate, isoleucine, glutamate, and glutarate between autistic and control individuals
were identified by West et al. [52]. They identified a decreased level of blood homocitrulline
as a new biomarker in autism. Homocitrulline is a poorly understood molecule that is known
to be formed inside the mitochondria from lysine and carbamoyl phosphate. The decreased
blood level of this marker also suggests that its metabolism in the brain may also be disrupted.
Homocitrulline levels are increased in urine and blood in patients with ornithine translocase
deficiency, which diverts the reaction between carbamyl phosphate and lysine. Patients with
ornithine translocase deficiency exhibit behavioral abnormalities similar to autism, such as
developmental delay, spasticity, learning, and cognitive abnormalities, together with frequent
seizures [53]. In addition, disrupted brain redox status and energy metabolism were reported
in rats that received homocitrulline intraventricularly [54, 55]. These observations suggest that
elevated brain levels of homocitrulline are deleterious; however, additional studies are needed
to define the brain levels of homocitrulline and its potential role in the development of autism.
The role of polyunsaturated fatty acids (PUFA) in neurodevelopment is becoming clear. The
brain and nervous tissue usually depend on ω-3 fatty acids, specifically docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA), for structural cell signaling purposes [56]. Among
the ascertained and reproducible markers in autism are the elevated ω-6 PUFA, LA (n-6)
together with ω-6:ω-3 ratio (n-6:n-3). Elevated n-6:n-3 ratios above 4–6:1 have been associated
with neuroinflammation as an etiopathogenesis mechanism in autism [57]. In several studies,
patients with autism exhibited elevated n-6:n-3 ratio and decreased n-3 fatty acid compared to
intellectually impaired control [58, 59]. Fombonne et al. [60] reported that the absence of
incidence of autism from 1991 to 2006 among an Inuit population was attributed to the
consumption of large amount of fish.
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Figure 5. Unbalance between ω-6/ω-3 fatty acids as etiological mechanism in autism.
Glutamate and GABA as the main excitatory and inhibitory neurotransmitters in the human
brain, respectively, have important roles during prenatal or postnatal brain development.
Upon excitation of the presynaptic neuron, glutamate is released from the synaptic vesicles
into the synaptic cleft. This is followed by the binding of the released glutamate to ionotropic
(NMDAR and AMPAR) or metabotropic receptors (mGluR) on the postsynaptic neurons. The
binding of glutamate to mGluRs triggers the activation of G-protein-dependent intracellular
signaling cascade. The activation of ionotropic glutamate receptors AMPA, kainate, and
NMDA by glutamate induces the opening of Na+ and Ca2+ ion channels. The overactivation of
glutamate receptors by excessive glutamate results in the influx of high levels of calcium ions
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
213
(Ca2+) into the postsynaptic cells, which in turn activate a cascade of proteases, lipases, nitric
oxide synthase, and a number of enzymes that damage cell structures leading to cell death.
Early studies described the neurotoxic effect of the excitatory neurotransmitter glutamate [61].
In 1969, Olney [62] found that the subcutaneous injection of monosodium glutamate resulted
in necrotic brain lesions in the hypothalamus of newborn mice, leading to a number of
developmental abnormalities. These reports led to the introduction of the term “excitotoxici‐
ty,” describing cell damage induced by an excess of glutamate as the most important excitatory
amino acids. The control of extracellular glutamate level at the synapse relatively depends on
Na+-dependent glutamate transporters located perisynaptically on astrocytes or neurons.
Dysfunction of these transporters usually contributed to severe excitotoxicity [63]. It is also
true that the activity of glutamate transporters is regulated by the extracellular concentration
of glutamate.
Glutamic acid decarboxylase (GAD) as a rate-limiting enzyme in glutamate/GABA cycle
catalyzes the conversion of glutamate to GABA. GAD65 and GAD67 are two isoforms of GAD,
expressed from two unlinked genes in the adult brain [64]. GAD67 is localized in chromosome
2q31.1, which is related to susceptibility for autism, so it might be a potential biomarker for
GABAergic abnormalities demonstrated in autistic patients [65]. The reduction in the number
of cerebellar Purkinje cells that express GAD67 abundantly has also been widely reported in
autism [66]. A high percentage decrease of mRNA expression for GAD67 was observed in
Purkinje cells of autistic individuals compared to control brains [67]. These findings suggest
that the reduction in the GABA input to cerebellar nuclei disrupts the output to cerebral cortex
and can be related to the motor and cognitive abnormalities seen in autistic patients. An early
study has also reported the reduction of GAD65 and GAD67 protein in the parietal cortex and
in the cerebellum of autistic brains [68]. There are also reports of increased glutamate levels in
the blood and platelets of autistic patients [69, 70]. In addition, a significantly lower glutamate/
glutamine ratio was reported by Abu-Shmais et al. [71]. Other studies have also shown that
an increased release from presynaptic neurons can also contribute to excitotoxicity. Moreover,
increased frequencies and amplitudes of action potential-evoked excitatory synaptic potentials
have been observed in mouse models of autism. Therefore, many studies were conducted to
clarify and analyze the functional status of glutamatergic and GABAergic neurotransmission
in the autistic brain [72, 73]. Based on these studies, strong evidence indicates that dysfunc‐
tional excitatory and inhibitory synaptic activities underlie several of the characteristics of
autism and support a hyperglutamatergic hypothesis of autism. This was attributed in some
studies highlighting an imbalance between GABAergic and glutamatergic as inhibitory and
excitatory neurotransmitters, respectively [73]. Another potential source of glutamate excito‐
toxicity is either the abnormal high release of glutamate or the decrease of glutamate trans‐
porters as proteins on the presynaptic neurons and astrocytes playing an important role in the
reuptake and removal of glutamate from the synaptic cleft. Raghavendra Rao et al. [74] showed
that glutamate transporter-1 (GLT-1) expression was significantly reduced (38–47%) in the rat
brain 24 h after fluid percussion injury. The resulting decrease in transport leads to an excess
of glutamate in the synaptic cleft. Either increased glutamate release from the presynaptic
neuron or removal by glutamate transporters, as two mechanisms that might be related to
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glutamate excitotoxicity, has been proven in rodent models of autism [75, 76]. Purcell et al. [77]
used 10 brain postmortem samples from individuals with autism to identify genes that were
significantly up-regulated or down-regulated. These researchers found abnormalities in the
AMPA-type glutamate receptors and glutamate transporters in the cerebellum of autistics
compared to control involving these transporters directly in the pathogenesis of this disorder.
This was ascertained when the down-regulation of glial glutamate transporters, GLT-1 and
GLAST, was found effective in the generation of animal models of autism in which glutamate
receptors are overstimulated [76].
Glutamate excitotoxicity can easily be related to low GSH level and this has been repeatedly
reported in autistic patients. It is well known that more than 80% of extracellular glutamate is
transported into astrocytes [78]. This in turn stimulates both GSH synthesis and cysteine
inward flow as a prerequisite for the maintenance of high GSH level in astrocytes [79]. On the
contrary, neurons import cysteine through EAAT2 and EAAT3 and this process is competi‐
tively inhibited by glutamate. Based on this, glutamate excitotoxicity will starve neurons of
cysteine in favor of ensuring high GSH level in astrocytes.
Several reproducible studies have ascertained that individuals with autism demonstrate an
abnormal brain 5-HT system [80, 81]. This was clinically presented as hyperserotonemia [80],
altered 5-HT synthesis or 5-HT receptor affinity, and dystrophic serotonergic [82–84]. In a
recent study on postmortem brains, a significant decrease in both 5-HT2A and 5-HT1A binding
was reported in autism [85]. Some researchers suggested an association of 5-HT dysfunction
with repetitive and self-injurious behaviors [86–88]. This gives support to the idea that
peripheral alterations in the 5-HT system may be an important marker of central abnormalities
in autism.
Oxytocin (OT) as a neuropeptide of great interest has been known to play important roles in
social behavior in both animals and humans [89, 90]. OT-related studies in autism have
repeatedly reported lower blood OT level in autistic patients compared to age- and gender-
matched control subjects [12, 81, 91, 92]. The faulty processing of the OT prohormone to the
active OT neuropeptide was also found [93] together with abnormalities and polymorphism
in the OT receptor (OTR) gene, raising the possibility of OT resistance in autism [94–98].
Multiple intersections of the 5-HT and OT systems have been ascertained and were found to
influence behaviors such as sociability, aggression, and anxiety that are relevant to autism [99,
100].
With the move toward the development of disease treatment strategy, there is a great need for
more specific diagnostic criteria of autism as a heterogeneous disorder. The diagnostic
accuracy of biomarkers is most commonly measured by calculating its sensitivity and specif‐
icity. Receiver operating characteristic (ROC) curve analysis is a useful tool in the assessment
of biomarker accuracy. The accuracy of a biomarker depends on how well it separates the
groups being tested into those with and without the disease in question. In ROC analysis, the
ratio of the abnormals found by the marker to the total number of abnormals known to have
the disease is the true positive rate (or sensitivity), whereas the ratio of the normals found by
the test to the total number of normals is the true negative rate (or specificity). The ROC curve
is a graph of sensitivity (y‐axis) versus 1-specificity (x‐axis). Accuracy is measured by the area
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under the ROC curve. An area of 0.9 to 1 represents a perfect marker, an area of 0.8 to 0.6
represents good-fair marker, and an area of 0.5 represents a worthless marker [101]. More
recently, combined ROC was introduced as a simple clinical method with great potential for
assisting the diagnosis of autism through the increase of the AUC, specificity, and sensitivity
and the diagnostic value of combined markers [102].
3. Biomarkers-directed treatment strategies
Positive roles between selected nutraceuticals or vitamins/minerals-based treatment strategies
and the improvement of autistic features have been reported. In a comparative case-control
treatment strategies, two groups each of 44 autistic patients, with an age range of 2 to 28 years,
were given either micronutrient supplement containing (14 vitamins, 16 dietary minerals, 3
amino acids, and 3 antioxidants) without any autism medication or conventional medication
without supplementation. Patients in both groups improved, but the level of improvement
was remarkably higher in micronutrient recommended group than in the conventional
medication group [103].
Similarly, in an observatory study, the administration of vitamin B12 and GSH along with low
fructose and food additive/color organic diet of 10 children (4–10 years of age) for 3 to 6 months
resulted in a significant improvement in the social interaction, concentration, writing, lan‐
guage, and behavior [104]. A meta-analysis of 18 studies revealed that the supplementation of
vitamin B6, especially in combination with magnesium, improved the health of autistic
patients [105, 106].
Complementary alternative medicine (CAM) treatments are usually recommended to promote
health, to avoid side the effects of conventional drugs, or to ameliorate the core symptoms of
autism. Prenatal exposure to VPA induces a rearrangement of early microbial colonization,
leading to an increase of butyrate levels in the gastrointestinal tract of male offspring. Conse‐
quently, increased levels of butyrate in the gut may interfere directly with gene expression in
intestinal cells or indirectly with gene expression of neuronal cells after crossing the BBB. This
is usually accompanied with induced deleterious changes in the intestinal and brain functions
that might explain certain autistic features. These results open the road to a novel strategy to
treat autism through gut microbiome manipulation. The administration of probiotic or
prebiotic may provide an excellent tool to treat autism based on our understanding of the role
of gut-brain axis and microbial metabolites in the pathology of this disorder.
Clinical studies have shown that prenatal supplementation with n-3 PUFA may be beneficial
for healthy neural development in both preterm and full-term infants [107–109]. Regarding
preterm infants, the timing of supplementation is of critical importance because these infants
cannot fully use accumulated long-chain PUFA that usually start in the last trimester of
gestation. Studies in full-term infants show that both prenatal and postnatal supplementations
cause an improvement in cognition [110, 111]. Moreover, in humans, the outcome of infant
n-3 PUFA supplementation on long-term brain development appears to be subtle [112–114]
compared to the rodent model studies [115], which demonstrate more pronounced beneficial
Role of Biomarkers in Medicine216
effects of n-3 PUFA supplementation [115–117]. Overall, our adequate dietary n-3 PUFA levels
starting early in life may support optimal neural development in healthy full-term infants.
In a randomized, double-blind, placebo-controlled 6-week pilot study, Amminger et al. [118]
investigated the effects of 1.5 g/d ω-3 fatty acids (0.84 g/d EPA and 0.7 g/d DHA) supplemen‐
tation given in the form of seven pale-yellow, 1 g gelatin capsules of fish oil, each containing
120 mg EPA and 100 mg DHA plus 1 mg vitamin E to 13 autistic children (aged 5–17 years).
The placebo was seven gelatin capsules of coconut oil that were of similar shape and size and
also contained 1 mg vitamin E as well as 1 mg fish oil to mimic fish taste. The experimental
daily dose of 1.5 g ω-3 fatty acids is based on a study in children with developmental coordi‐
nation disorder by Richardson and Montgomery [119]. The findings of their trial suggested
that ω-3 fatty acids may be effective in treating the aggression and impulsivity in autistic
patients. The underlying mechanism of action is not fully understood but may be related to
the modulation of serotonergic and dopaminergic neurotransmission [120]. This can be
ascertained by considering the phenomenon that DHA or the EPA/ARA ratio might control
aggression by depressing the noradrenergic system [112]. The more recent work of El-Ansary
et al. [116] supports that the essential fatty acids/long-chain PUFA and ω-3/ω-6 ratios,
phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine could be used as
potential biomarkers that point to specific mechanisms in the development of autism and may
help tailor treatment or prevention strategies (Figure 5). In the recent study of Weiser et al.
[121], DHA supplementation greatly reduced the level of IL-6 as an acute inflammatory marker
induced in the rodent model of autism exposed to the viral mimetic polyriboinosinic-polyri‐
bocytidylic acid during gestation. This gives preliminary evidence that ω-3 fatty acids may be
an effective treatment strategy for children with autism.
A recent report by the Autism Genome Project Consortium identified a new linkage peak for
autism in the region of chromosome 11 where the gene for EAAT2 is located [122]. Signs of
astroglial, oligodendroglial, and microglial dysfunction were reported in the autistic brain,
suggesting that all these cellular processes may represent presumptive targets for novel
therapeutic strategies [123]. Additionally, a study investigating the effects of ceftriaxone and
cefixime, activators of GLT-1, demonstrated that these drugs improved some symptoms of
autism and decreased epilepsy seizures by increasing the expression of the GLT-1, which
reduces extracellular glutamate levels [124].
Elevated levels of glutamate are present in high proteins, including wheat gluten and milk
casein. This can explain the sensitivity of autistic children to both proteins as a rich source of
glutamate. Some parents of autistic children try gluten/casein-restricted diet in an attempt to
improve their child’s behavior, but evidence is lacking that following such diet improves the
child’s challenging behaviors, cognitive and social functioning as core symptoms of autism
[125]. Furthermore, following a gluten casein-free diet may place children at risk for subopti‐
mal bone development [126].
Several animal models and research in typically developing volunteers suggest that the
manipulation of the OT system may have a potential therapeutic effect in treating social deficits
in autistic patients. Twelve weeks of intranasal treatment with OT (0.4 IU/kg/dose) was found
effective in improving social impairment, repetitive behavior, and anxiety in children and
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adolescents with autism. Some measures suggest the safety and maintenance of the effect for
3 months after the discontinuation of intranasal OT treatment [127]. Meziane et al. [128]
reported that an early OT treatment just after birth could be a novel therapeutic approach for
the treatment of autism.
In a recent study, Carminati et al. [129] tested the therapeutic efficacy of venlafaxine, an
antidepressant drug that inhibits the reuptake of 5-HT, and proved that venlafaxine at a low
dose represents a substantial improvement in repetitive behaviors, restricted interests, social
impairment, communication, and language. Venlafaxine probably acts via serotonergic
mechanisms by affecting the selective 5-HT reuptake inhibitors. Figure 6 summarizes the
biomarkers directed to treat autism.
Figure 6. Biomarkers-directed strategies to treat autism.
Author details
Afaf El-Ansary1,2* and Hussain Al Dera3,4
*Address all correspondence to: afafkelansary@gmail.com
1 Therapuetic Chemistry Department, National Research Centre, Dokki, Cairo, Egypt
2 Biochemistry Department, Science College, King Saud University, Riyadh, Saudi Arabia
3 Basic Medical Department, College of Medicine, King Saud bin Abdul Aziz University for
Health Sciences, Riyadh, Saudi Arabia
4 King Abdullah International Medical Research Center (Kaimrc), Ministry of National
Guard, Riyadh, Saudi Arabia
Role of Biomarkers in Medicine218
References
[1] Aspy R, Grossman BG. Designing Comprehensive Interventions for High-Functioning
Individuals with Autism Spectrum Disorders: The Ziggurat Model. USA, AAPC Publishing;
2011.
[2] Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, Endris V, Roberts W,
Szatmari P, Pinto D. Mutations in the SHANK2 synaptic scaffolding gene in autism
spectrum disorder and mental retardation. Nat Genet 2010;42:489–491.
[3] Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J, Magalhaes
TR, Correia C, Abrahams BS. Functional impact of global rare copy number variation
in autism spectrum disorders. Nature 2010;466:368–372.
[4] Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D. Rare de novo variants
associated with autism implicate a large functional network of genes involved in
formation and function of synapses. Neuron 2011;70:898–907.
[5] State MW, Šestan N. The emerging biology of autism spectrum disorders. Science
2012;337:1301.
[6] Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, Chu
SH, Moreau MP, Gupta AR, Thomson SA. Multiple recurrent de novo CNVs, including
duplications of the 7q11. 23 Williams syndrome region, are strongly associated with
autism. Neuron 2011;70:863–885.
[7] Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res
2009;65:591–598.
[8] Kim YS, Leventhal BL, Koh Y-J, Fombonne E, Laska E, Lim E-C, Cheon K-A, Kim S-J,
Kim Y-K, Lee H. Prevalence of autism spectrum disorders in a total population sample.
Am J Psychiatry 2011;168:904–912.
[9] Main P, Angley MT, O’Doherty CE, Thomas P, Fenech M. The potential role of the
antioxidant and detoxification properties of glutathione in autism spectrum disorders:
a systematic review and meta-analysis. Nutr Metab (Lond) 2012;9:35.
[10] Lord RS, Bralley JA. Clinical applications of urinary organic acids. Part I: detoxification
markers. Altern Med Rev 2008;13:205–215.
[11] Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM. Oxidative stress in Egyptian
children with autism: relation to autoimmunity. J Neuroimmunol 2010;219:114–118.
[12] Alabdali A, Al-Ayadhi L, El-Ansary A. Association of social and cognitive impairment
and biomarkers in autism spectrum disorders. J Neuroinflamm 2014;11.
[13] Q-b Zhang, Gao S-j, H-x Zhao. Thioredoxin: a novel, independent diagnosis marker in
children with autism. Int J Dev Neurosci 2015;40:92–96.
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
219
[14] Rossignol D, Frye R. Mitochondrial dysfunction in autism spectrum disorders: a
systematic review and meta-analysis. Mol Psychiatry 2012;17:290–314.
[15] Mulle JG, Sharp WG, Cubells JF. The gut microbiome: a new frontier in autism research.
Curr Psychiatry Rep 2013;15:1–9.
[16] Burokas A, Moloney RD, Dinan TG, Cryan JF. Chapter one—microbiota regulation of
the mammalian gut-brain axis. Adv Appl Microbiol 2015;91:1–62.
[17] Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters
fetal brain development through interleukin-6. J Neurosci 2007;27:10695–10702.
[18] Libbey JE, Fujinami RS. Role for antibodies in altering behavior and movement. Autism
Res 2010;3:147–152.
[19] Angelidou A, Asadi S, Alysandratos K-D, Karagkouni A, Kourembanas S, Theoharides
TC. Perinatal stress, brain inflammation and risk of autism-Review and proposal. BMC
Pediatr 2012;12:89.
[20] Fetissov SO, Sinno MH, Coëffier M, Bole-Feysot C, DucrottéP, Hökfelt T, Déchelotte P.
Autoantibodies against appetite-regulating peptide hormones and neuropeptides:
putative modulation by gut microflora. Nutrition 2008;24:348–359.
[21] de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De
Rosa M, Francavilla R, Riegler G. Alterations of the intestinal barrier in patients with
autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol
Nutr 2010;51:418–424.
[22] Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol
2009;9:799–809.
[23] Hsiao EY, Mc Bride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J,
Reisman SE, Petrosino JF. Microbiota modulate behavioral and physiological abnor‐
malities associated with neurodevelopmental disorders. Cell 2013;155:1451–1463.
[24] Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut
microflora of children with autistic spectrum disorders and that of healthy children. J
Med Microbiol 2005;54:987–991.
[25] Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E,
Summanen PH, Granpeesheh D, Dixon D. Pyrosequencing study of fecal microflora of
autistic and control children. Anaerobe 2010;16:444–453.
[26] Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and
gastrointestinal status in children with autism—comparisons to typical children and
correlation with autism severity. BMC Gastroenterol 2011;11:22.
[27] Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Low
relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobac‐
terium spp. in feces of children with autism. Appl Environ Microbiol 2011;77:6718–6721.
Role of Biomarkers in Medicine220
[28] Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, Bennett A, Jabado
O, Hirschberg DL, Lipkin WI. Impaired carbohydrate digestion and transport and
mucosal dysbiosis in the intestines of children with autism and gastrointestinal
disturbances. PLoS One 2011;6:e24585.
[29] Williams BL, Hornig M, Parekh T, Lipkin WI. Application of novel PCR-based methods
for detection, quantitation, and phylogenetic characterization of Sutterella species in
intestinal biopsy samples from children with autism and gastrointestinal disturbances.
MBio 2012;3:e00261–00211.
[30] Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen M-L, Bolte E, McTeague M, Sandler
R, Wexler H, Marlowe EM. Gastrointestinal microflora studies in late-onset autism.
Clin Infect Dis 2002;35:S6–S16.
[31] De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI,
Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R. Fecal microbiota and metabo‐
lome of children with autism and pervasive developmental disorder not otherwise
specified. PLoS One 2013;8:e76993.
[32] Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary meta‐
bolic phenotyping differentiates children with autism from their unaffected siblings
and age-matched controls. J Proteome Res 2010;9:2996–3004.
[33] Beloborodova N, Bairamov I, Olenin A, Shubina V, Teplova V, Fedotcheva N. Effect of
phenolic acids of microbial origin on production of reactive oxygen species in mito‐
chondria and neutrophils. J Biomed Sci 2012;19:89.
[34] MacFabe DF. Short-chain fatty acid fermentation products of the gut microbiome:
implications in autism spectrum disorders. Microb Ecol Health Dis 2012;23. doi: 10.3402/
mehd.v23i0.19260.
[35] MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, Taylor
AR, Kavaliers M, Ossenkopp K-P. Neurobiological effects of intraventricular propionic
acid in rats: possible role of short chain fatty acids on the pathogenesis and character‐
istics of autism spectrum disorders. Behav Brain Res 2007;176:149–169.
[36] MacFabe DF, Cain NE, Boon F, Ossenkopp K-P, Cain DP. Effects of the enteric bacterial
metabolic product propionic acid on object-directed behavior, social behavior, cogni‐
tion, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder.
Behav Brain Res 2011;217:47–54.
[37] Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in
children across the United States with autism spectrum disorders from families with
multiple affected members. J Dev Behav Pediatr 2011;32:351–360.
[38] Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T. Autism-like behaviours
with transient histone hyperacetylation in mice treated prenatally with valproic acid.
J Neuropsychopharmacol 2013;16:91–103.
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
221
[39] Burger-van Paassen N, Vincent A, Puiman P, Van Der Sluis M, Bouma J, Boehm G, van
Goudoever J, Van Seuningen I, Renes I. The regulation of intestinal mucin MUC2
expression by short-chain fatty acids: implications for epithelial protection. Biochem J
2009;420:211–219.
[40] D’Souza A, Onem E, Patel P, La Gamma EF, Nankova BB. Valproic acid regulates
catecholaminergic pathways by concentration-dependent threshold effects on TH
mRNA synthesis and degradation. Brain Res 2009;1247:1–10.
[41] Liu H, Hu Q, Kaufman A, D’Ercole AJ, Ye P. Developmental expression of histone
deacetylase 11 in the murine brain. J Neurosci Res 2008;86:537–543.
[42] Patterson PH. Maternal infection: window on neuroimmune interactions in fetal brain
development and mental illness. Curr Opin Neurobiol 2002;12:115–118.
[43] Stolp H, Dziegielewska K. Review: role of developmental inflammation and blood-
brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases.
Neuropathol Appl Neurobiol 2009;35:132–146.
[44] Hornig M, Briese T, Buie T, Bauman ML, Lauwers G, Siemetzki U, Hummel K, Rota
PA, Bellini WJ, O’Leary JJ. Lack of association between measles virus vaccine and
autism with enteropathy: a case-control study. PLoS One 2008;3:e3140.
[45] Malik M, Sheikh AM, Wen G, Spivack W, Brown WT, Li X. Expression of inflammatory
cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects.
Immunobiology 2011;216:80–85.
[46] Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production
associated with innate and adaptive immune responses in children with autism
spectrum disorders and developmental regression. J Neuroimmunol 2001;120:170–179.
[47] Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, Courchesne
E, Everall IP. Microglial activation and increased microglial density observed in the
dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010;68:368–376.
[48] Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial
activation and neuroinflammation in the brain of patients with autism. Ann Neurol
2005;57:67–81.
[49] Chez MG, Guido-Estrada N. Immune therapy in autism: historical experience and
future directions with immunomodulatory therapy. Neurotherapeutics 2010;7:293–301.
[50] Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, Persico AM. Immune
transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis
2008;30:303–311.
[51] Suganya V, Geetha A, Sujatha S. Urine proteome analysis to evaluate protein biomark‐
ers in children with autism. Clin Chim Acta 2015;450:210–219.
Role of Biomarkers in Medicine222
[52] West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, Palmer JA, Fontaine BR,
Conard KR, Corbett BA. Metabolomics as a tool for discovery of biomarkers of autism
spectrum disorder in the blood plasma of children. PLoS One 2014;9:e112445.
[53] Palmieri F. The mitochondrial transporter family (SLC25): physiological and patho‐
logical implications. Pflügers Arch 2004;447:689–709.
[54] Viegas CM, Busanello ENB, Tonin AM, de Moura AP, Grings M, Ritter L, Schuck PF,
da CostaFerreira G, Sitta A, Vargas CR. Dual mechanism of brain damage induced in
vivo by the major metabolites accumulating in hyperornithinemia-hyperammonemia-
homocitrullinuria syndrome. Brain Res 2011;1369:235–244.
[55] Sokoro AA, Lepage J, Antonishyn N, McDonald R, Rockman-Greenberg C, Irvine J,
Lehotay DC. Diagnosis and high incidence of hyperornithinemia-hyperammonemia-
homocitrullinemia (HHH) syndrome in northern Saskatchewan. J Inherit Metab Dis
2010;33:275–281.
[56] Brenna JT, Carlson SE. Docosahexaenoic acid and human brain development: evidence
that a dietary supply is needed for optimal development. J Hum Evol 2014;77:99–106.
[57] Simopoulos AP. Evolutionary aspects of diet: the ω-6/ω-3 ratio and the brain. Mol
Neurobiol 2011;44:203–215.
[58] Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres
C, Chalon S. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent
Fatty Acids 2001;65:1–7.
[59] Ghezzo A, Visconti P, Abruzzo PM, Bolotta A, Ferreri C, Gobbi G, Malisardi G,
Manfredini S, Marini M, Nanetti L. Oxidative stress and erythrocyte membrane
alterations in children with autism: correlation with clinical features. PLoS One
2013;8:e66418.
[60] Fombonne E, Morel J, Macarthur J. No autism amongst Inuits from northern Quebec.
In Fifth International Meeting for Autism Research, Montreal, Quebec; 2006.
[61] Lucas D, Newhouse J. The toxic effect of sodium L-glutamate on the inner layers of the
retina. AMA Arch Ophthalmol 1957;58:193–201.
[62] Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monoso‐
dium glutamate. Science 1969;164:719–721.
[63] Blaylock R, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism
of the autism spectrum disorders. Curr Med Chem 2009;16:157–170.
[64] Bu D-F, Erlander MG, Hitz BC, Tillakaratne N, Kaufman DL, Wagner-McPherson CB,
Evans GA, Tobin AJ. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa
GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A 1992;89:2115–2119.
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
223
[65] Rabionet R, Jaworski JM, Ashley-Koch AE, Martin ER, Sutcliffe JS, Haines JL, DeLong
GR, Abramson RK, Wright HH, Cuccaro ML. Analysis of the autism chromosome 2
linkage region: GAD1 and other candidate genes. Neurosci Lett 2004;372:209–214.
[66] Kern JK. Purkinje cell vulnerability and autism: a possible etiological connection. Brain
Dev 2003;25:377–382.
[67] Yip J, Soghomonian J-J, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje
cells in autism: pathophysiological implications. Acta Neuropathol 2007;113:559–568.
[68] Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid
decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar
cortices. Biol Psychiatry 2002;52:805–810.
[69] Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children
with autism and their families. J Autism Dev Disord 2003;33:93–97.
[70] Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda
S, Suzuki K, Sugihara G-I. Increased serum levels of glutamate in adult patients with
autism. Prog Neuro-psychopharmacol Biol Psychiatry 2006;30:1472–1477.
[71] Abu-Shmais GA, Al-Ayadhi LY, Al-Dbass AM, El-Ansary AK. Mechanism of nitrogen
metabolism-related parameters and enzyme activities in the pathophysiology of
autism. J Neurodev Disord 2012;4:4.
[72] Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spec‐
trum disorders: implications for interventions and therapeutics. World J Biol Psychia‐
try 2015:1–13.
[73] El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders.
Neuroinflammation 2012;9:265.
[74] Raghavendra Rao VL, Başkaya MK, Doğan A, Rothstein JD, Dempsey RJ. Traumatic
brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins
in rat brain. J Neurochem 1998;70:2020–2027.
[75] Wei H, Ding C, Jin G, Yin H, Liu J, Hu F. Abnormal glutamate release in aged BTBR
mouse model of autism. Int J Clin Exp Pathol 2015;8:10689.
[76] Tanaka K. Role of glutamate transporters in the pathophysiology of major mental
illnesses. Nihon Shinkei Seishin Yakurigaku Zasshi 2009;29:161–164.
[77] Purcell A, Jeon O, Zimmerman A, Blue M, Pevsner J. Postmortem brain abnormalities
of the glutamate neurotransmitter system in autism. Neurology 2001;57:1618–1628.
[78] Hertz L, Peng L. Energy metabolism at the cellular level of the CNS. Can J Physiol
Pharmacol 1992;70:S145–S157.
[79] Bannai S, Tateishi N. Role of membrane transport in metabolism and function of
glutathione in mammals. J Membr Biol 1986;89:1–8.
Role of Biomarkers in Medicine224
[80] Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder:
a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014;24:919–929.
[81] Yang C-J, Tan H-P, Yang F-Y, Wang H-P, Liu C-L, He H-Z, Sang B, Zhu X-M, Du Y-J.
The cortisol, serotonin and oxytocin are associated with repetitive behavior in autism
spectrum disorder. Res Autism Spectr Disord 2015;18:12–20.
[82] Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, Da Silva
EA, Chugani HT. Altered serotonin synthesis in the dentatothalamocortical pathway
in autistic boys. Ann Neurol 1997;42:666–669.
[83] Makkonen I, Riikonen R, Kokki H, Airaksinen MM, Kuikka JT. Serotonin and dopamine
transporter binding in children with autism determined by SPECT. Dev Med Child
Neurol 2008;50:593–597.
[84] Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, Tsuchiya KJ,
Sugihara G, Iwata Y, Suzuki K. Brain serotonin and dopamine transporter bindings in
adults with high-functioning autism. Arch Gen Psychiatry 2010;67:59–68.
[85] Oblak A, Gibbs TT, Blatt GJ. Reduced serotonin receptor subtypes in a limbic and a
neocortical region in autism. Autism Res 2013;6:571–583.
[86] Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, Smith CJ,
Cook EH, Silverman JM. Relationship between whole blood serotonin and repetitive
behaviors in autism. Psychiatry Res 2010;175:274–276.
[87] Sacco R, Curatolo P, Manzi B, Militerni R, Bravaccio C, Frolli A, Lenti C, Saccani M, Elia
M, Reichelt KL. Principal pathogenetic components and biological endophenotypes in
autism spectrum disorders. Autism Res 2010;3:237–252.
[88] Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR,
Cohen J, Mannangatti P, Jessen T, Thompson BJ. Autism gene variant causes hyper‐
serotonemia, serotonin receptor hypersensitivity, social impairment and repetitive
behavior. Proc Natl Acad Sci U S A 2012;109:5469–5474.
[89] Insel TR. The challenge of translation in social neuroscience: a review of oxytocin,
vasopressin, and affiliative behavior. Neuron 2010;65:768–779.
[90] Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in
the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci
2011;12:524–538.
[91] Modahl C, Green LA, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H. Plasma
oxytocin levels in autistic children. Biol Psychiatry 1998;43:270–277.
[92] Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social
behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad
Sci U S A 2010;107:4389–4394.
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
225
[93] Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic
disorder: alterations in peptide forms. Biol Psychiatry 2001;50:609–613.
[94] Wu S, Jia M, Ruan Y, Liu J, Guo Y, Shuang M, Gong X, Zhang Y, Yang X, Zhang D.
Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese
Han population. Biol Psychiatry 2005;58:74–77.
[95] Jacob S, Brune CW, Carter C, Leventhal BL, Lord C, Cook EH. Association of the
oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism.
Neurosci Lett 2007;417:6–9.
[96] Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein R. Association between the
oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behav‐
ior Scales and cognition. Mol Psychiatry 2008;13:980–988.
[97] Yrigollen CM, Han SS, Kochetkova A, Babitz T, Chang JT, Volkmar FR, Leckman JF,
Grigorenko EL. Genes controlling affiliative behavior as candidate genes for autism.
Biol Psychiatry 2008;63:911–916.
[98] Ebstein RP, Knafo A, Mankuta D, ChewSH, SanLai P. The contributions of oxytocin
and vasopressin pathway genes to human behavior. Horm Behav 2012;61:359–379.
[99] Dölen G, Darvishzadeh A, Huang KW, Malenka RC. Social reward requires coordi‐
nated activity of nucleus accumbens oxytocin and serotonin. Nature 2013;501:179–184.
[100] Dölen G. Autism: oxytocin, serotonin, and social reward. Soc Neurosci 2015;10:450–465.
[101] Pepe M, Longton G, Janes H. Estimation and comparison of receiver operating
characteristic curves. Stata J 2009;9:1.
[102] Yang CJ, Liu CL, Sang B, Zhu XM, Du YJ. The combined role of serotonin and inter‐
leukin-6 as biomarker for autism. Neuroscience 2015;284:290–296.
[103] Mehl-Madrona L, Leung B, Kennedy C, Paul S, Kaplan BJ. Micronutrients versus
standard medication management in autism: a naturalistic case-control study. J Child
Adolesc Psychopharmacol 2010;20:95–103.
[104] Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit
hyperactivity disorder: a prepilot study. J Altern Complement Med 2007;13:1091–1098.
[105] Kidd PM. Autism, an extreme challenge to integrative medicine. Part II: medical
management. Altern Med Rev 2002;7:472–499.
[106] Cornish S, Mehl-Madrona L. The role of vitamins and minerals in psychiatry. Integr
Med Insights 2008;3:33.
[107] Henriksen C, Haugholt K, Lindgren M, Aurvåg AK, Rønnestad A, Grønn M, Solberg
R, Moen A, Nakstad B, Berge RK. Improved cognitive development among preterm
infants attributable to early supplementation of human milk with docosahexaenoic acid
and arachidonic acid. Pediatrics 2008;121:1137–1145.
Role of Biomarkers in Medicine226
[108] Isaacs EB, Ross S, Kennedy K, Weaver LT, Lucas A, Fewtrell MS. 10-year cognition in
preterms after random assignment to fatty acid supplementation in infancy. Pedia‐
trics 2011;128:e890–e898.
[109] Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P. Effect of DHA
supplementation during pregnancy on maternal depression and neurodevelopment of
young children: a randomized controlled trial. JAMA 2010;304:1675–1683.
[110] Dunstan J, Simmer K, Dixon G, Prescott S. Cognitive assessment of children at age 2½
years after maternal fish oil supplementation in pregnancy: a randomised controlled
trial. Arch Dis Child 2008;93:F45–F50.
[111] Smithers LG, Gibson RA, Makrides M. Maternal supplementation with docosahexae‐
noic acid during pregnancy does not affect early visual development in the infant: a
randomized controlled trial. Am J Clin Nutr 2011;93:1293–1299.
[112] Wurtman RJ. Synapse formation and cognitive brain development: effect of docosa‐
hexaenoic acid and other dietary constituents. Metabolism 2008;57:S6–S10.
[113] Bouwstra H, Dijck-Brouwer DJ, Decsi T, Boehm G, Boersma ER, Muskiet FA, Hadders-
Algra M. Relationship between umbilical cord essential fatty acid content and the
quality of general movements of healthy term infants at 3 months. Pediatr Res
2006;59:717–722.
[114] Fewtrell MS, Morley R, Abbott RA, Singhal A, Isaacs EB, Stephenson T, MacFadyen U,
Lucas A. Double-blind, randomized trial of long-chain polyunsaturated fatty acid
supplementation in formula fed to preterm infants. Pediatrics 2002;110:73–82.
[115] Carrié I, Guesnet P, Bourre J-M, Francès H. Diets containing long-chain n-3 polyunsa‐
turated fatty acids affect behaviour differently during development than ageing in
mice. Br J Nutr 2000;83:439–447.
[116] El-Ansary AK, Al-Daihan SK, El-Gezeery AR. On the protective effect of ω-3 against
propionic acid-induced neurotoxicity in rat pups. Lipids Health Dis 2011;10:19.
[117] Coluccia A, Borracci P, Renna G, Giustino A, Latronico T, Riccio P, Carratù MR.
Developmental ω-3 supplementation improves motor skills in juvenile-adult rats. Int
J Dev Neurosci 2009;27:599–605.
[118] Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M. ω-3 fatty acids
supplementation in children with autism: a double-blind randomized, placebo-
controlled pilot study. Biol Psychiatry 2007;61:551–553.
[119] Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled
trial of dietary supplementation with fatty acids in children with developmental
coordination disorder. Pediatrics 2005;115:1360–1366.
[120] Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N. Essential fatty
acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among
Biomarkers-Directed Strategies to Treat Autism
http://dx.doi.org/10.5772/62566
227
healthy control subjects, and early-and late-onset alcoholics. Biol Psychiatry
1998;44:235–242.
[121] Weiser MJ, Wynalda K, Salem N, Butt CM. Dietary DHA during development affects
depression-like behaviors and biomarkers that emerge after puberty in adolescent rats.
J Lipid Res 2015;56:151–166.
[122] Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu X-Q, Vincent JB,
Skaug JL, Thompson AP, Senman L. Mapping autism risk loci using genetic linkage
and chromosomal rearrangements. Nat Genet 2007;39:319–328.
[123] Zeidán-Chuliá F, Salmina AB, Malinovskaya NA, Noda M, Verkhratsky A, Moreira
JCF. The glial perspective of autism spectrum disorders. Neurosci Biobehav Rev
2014;38:160–172.
[124] Ghanizadeh A, Michael B. β-Lactam antibiotics as a possible novel therapy for man‐
aging epilepsy and autism: a case report and review of literature. Iran J Child Neurol
2015;9:99.
[125] Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten-and casein-free diets for
autistic spectrum disorder. Cochrane Database Syst Rev 2008;2.
[126] Geraghty ME, Depasquale GM, Lane AE. Nutritional intake and therapies in autism a
spectrum of what we know: part 1. Infant Child Adolesc Nutr 2010;2:62–69.
[127] Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S, Jacob S. Intranasal
oxytocin in the treatment of autism spectrum disorders: a review of literature and early
safety and efficacy data in youth. Brain Res 2014;1580:188–198.
[128] Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, Guillon G, Lafitte D,
Desarmenien MG, Tauber M. An early postnatal oxytocin treatment prevents social
and learning deficits in adult mice deficient for Magel2, a gene involved in Prader-Willi
syndrome and autism. Biol Psychiatry 2014.
[129] Carminati GG, Gerber F, Darbellay B, Kosel MM, Deriaz N, Chabert J, Fathi M, Bertschy
G, Ferrero F, Carminati F. Using venlafaxine to treat behavioral disorders in patients
with autism spectrum disorder. Prog Neuro-psychopharmacol Biol Psychiatry 2016;65:85–
95.
Role of Biomarkers in Medicine228
